Journal
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION
Volume 7, Issue 3, Pages -Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/NXI.0000000000000695
Keywords
-
Categories
Ask authors/readers for more resources
Ocrelizumab has been recently approved for relapsing-remitting MS, demonstrating a dramatic effect on MRI and clinical parameters in 2 pivotal phase III trials.(1)However, long-term B-cell depletion might lead to an increased susceptibility to infections and/or to their increased severity (a case of fulminant hepatitis due to enterovirus infection has been recently reported by our group).(2)Finally, depletion of B-cell compartment might impair acquisition of long-term humoral immunologic memory (i.e. production of antigen-specific class G immunoglobulins [IgG]) and might reduce T-lymphocyte response because of the absence of B lymphocyte-mediated activation. Indeed, humoral response to vaccination has been shown to be dampened or abolished in ocrelizumab-treated patients.(3)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available